---
title: "Photocure says Asieris counterclaims in arbitration, seeks return of USD 6.6 million milestone payment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294775299.md"
description: "Photocure and Asieris are engaged in arbitration regarding an $11 million milestone payment for Cevira's China approval. While Photocure invoiced the full amount, Asieris paid only $6.6 million, arguing the label did not trigger the total sum. Photocure filed for arbitration to recover the balance, while Asieris counterclaimed seeking the return of the $6.6 million already paid."
datetime: "2026-08-04T06:02:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294775299.md)
  - [en](https://longbridge.com/en/news/294775299.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294775299.md)
---

# Photocure says Asieris counterclaims in arbitration, seeks return of USD 6.6 million milestone payment

-   Photocure faces an Asieris counterclaim in arbitration over an $11 million milestone tied to China approval of Cevira. \* Photocure invoiced $11 million; Asieris paid $6.6 million, arguing the China label does not trigger the full amount. \* Photocure filed arbitration on July 23 seeking the unpaid balance; Asieris’ Aug. 3 response seeks return of the $6.6 million. \* Photocure maintains the milestone was achieved, keeping the dispute centered on payment timing and contract interpretation. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Photocure ASA published the original content used to generate this news brief via Cision (Ref. ID: 20260804:BIT:3962:0) on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [688176.CN](https://longbridge.com/en/quote/688176.CN.md)

## Related News & Research

- [Elon Musk Says ‘AI Will Do It’ After Anthropic CEO Dario Amodei Says AI Industry Must ‘Actually’ Cure Cancer to Win Public Trust](https://longbridge.com/en/news/296328539.md)
- [GUBRA: Biotech revenue normalized post-AbbVie deal; CRO rebounded with 11% growth and profitability](https://longbridge.com/en/news/296439475.md)
- [ExpreS2ion says ES2B-C001 Phase I trial shows anti-HER2 antibody response in 12 of 13 patients, no dose-limiting toxicities](https://longbridge.com/en/news/296452642.md)
- [11:20 ETIndustry Veteran Jeff Mellios Joins The SSI Group to Lead Next Chapter of Payer Solutions Business Growth](https://longbridge.com/en/news/296375435.md)
- [WuXi Biologics agrees to sell 51.1% stake in Bestchrom](https://longbridge.com/en/news/296076443.md)